In an exciting milestone for cardiovascular innovation, Entero Therapeutics, operating within the Tenaya Therapeutics family, has secured $2,000,000 in new funding. Founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center, our clinical-stage biotechnology company is renowned for its bold commitment to revolutionizing heart disease treatment. This significant investment not only validates our vision to change the treatment paradigm for heart disease but also fortifies our mission to discover, design, develop, and deliver curative therapies that target the underlying drivers of this debilitating condition.
With this fresh infusion of capital, Entero Therapeutics is poised to enhance its core internal capabilities and accelerate the advancement of our promising pipeline of disease-modifying therapies. By leveraging our innovative product platforms, we aim to target defined sub-populations of patients suffering from both rare and highly prevalent forms of heart disease. These funds will be strategically deployed to support critical clinical trials, optimize our research and development processes, and expand our capacity to engage with regulatory agencies and healthcare partners. Ultimately, our goal is to improve and extend the lives of millions of individuals and families affected by heart disease.
This funding milestone underscores the unwavering confidence of our investors and partners in our scientific approach and strategic vision. As we continue to push the boundaries of biotechnology and cardiovascular research, we remain dedicated to our mission of delivering transformational therapies that address the root causes of heart disease. We are grateful for the continued support that propels us forward in this vital endeavor, and we look ahead with optimism as we work tirelessly to bring hope and healing to patients worldwide.
